GlassScriptPhysician profile
Robert M Easton
NPI 1134121247
$6,648.16
in general payments reported to CMS, 2019-2025
27 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $213 · 2021: $1,028 · 2022: $1,079 · 2023: $1,033 · 2024: $510 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564 · Travel and Lodging: $81.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.47 |
| Travel and Lodging | $81.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,263.05 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,106.49 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Encore Medical, LP | $841.71 | 2021-2023 | Djo Surgical |
| Johnson & Johnson Vision Care, INC. | $696.98 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $395.73 | 2019-2025 | Dailies Total1, Tryptyr, Precision7 |
| Dompe US, INC. | $261.26 | 2021-2025 | Oxervate |
| Glaukos Corporation | $243.47 | 2022-2025 | Kxl System (Not Refurbished) |
| Horizon Therapeutics Plc | $240.25 | 2021-2022 | |
| Oyster Point Pharma, INC. | $161.16 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $157.43 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Biotissue Holdings INC. | $152.59 | 2024 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | |
| Maculogix, INC. | $113.04 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $111.10 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $92.97 | 2025 | |
| Optos, INC. | $87.41 | 2022 | |
| Topcon Healthcare, INC. | $75.46 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $74.45 | 2019 | |
| Optovue, INC. | $74.07 | 2020 | |
| Zimmer Biomet Holdings, INC. | $70.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $49.65 | 2019 | |
| Visionix USA, INC | $41.67 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $31.25 | 2025 | Xdemvy |
| Allergan, INC. | $20.84 | 2022 | |
| Shire North American Group INC | $20.16 | 2019 | |
| Notal Vision, INC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Easton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.